- Alkylating Agents
- Purine Nucleoside Analogs
Cold Agglutinin Disease (CAD) Market was valued at USD 86 million in 2022 and is poised to grow at a CAGR of 19.6% over 2023-2029. Cold agglutinin disease (CAD) is a rare autoimmune disorder characterized by the presence of high concentrations of circulating cold-sensitive antibodies, directed against red blood cells, only at low body temperature (28-31?), causing them to agglutinate and undergo lysis. According to the American Society of Hematology, cold agglutinin disease has a prevalence of 5 to 20 cases per million and an incidence of 0.5 to 1.9 cases per million per year. The increasing prevalence of cold agglutinin disease risk factors such as cancer, bacterial infections, parasitic infections, viral diseases, and other autoimmune disorders, and the geriatric population will act as the cold agglutinin disease market growth drivers. However, the high cost of treatment and lack of awareness could be the restraining factor for the market. An increasing number of R&D activities by the key market players will be an opportunity for expansion of the market.
Fastest Growing Market
There has been an increase in investment in healthcare infrastructure and the increasing number of drug approvals are the factors that will drive the future growth of the cold agglutinin disease market. For example, in Jun 2022, Sanofi’s Enjaymo was approved by Japan’s MHLW, and in Nov 2022, the European Commission granted the marketing authorization, for the treatment of cold agglutinin disease. Furthermore, there are other emerging therapies such as Aspaveli (Pegcetacoplan), by SOBI and Apellis Pharmaceuticals, and LNP023 (Iptacopan) by Novartis in clinical trial phases for cold agglutinin disease. Thus, the increased research and development for rare disorders will lead to the growth of the market within the forecast period. Whereas, a lack of skilled professionals could have a negative impact on the market.
The Cold Agglutinin Disease (CAD) market was valued at USD 86 million in 2022 and is expected to grow at a 19.6% CAGR over the forecast period 2023 – 2029.
An increasing number of R&D activities by the key market players is the key opportunity for the Cold Agglutinin Disease (CAD) market.
The increasing prevalence of cold agglutinin disease risk factors such as cancer, bacterial infections, parasitic infections, viral diseases, and other autoimmune disorders, and the geriatric population are the growth drivers in the Cold Agglutinin Disease (CAD) market.
Roche Holding AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., GSK plc., Novartis AG, Zydus Lifesciences Limited, AstraZeneca plc., Johnson & Johnson, Bayer AG, Apellis Pharmaceuticals, Inc., and Incyte Corporation are a few companies operating in the Cold Agglutinin Disease (CAD) market.